(19)
(11) EP 2 804 596 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
15.05.2019 Bulletin 2019/20

(45) Mention of the grant of the patent:
06.03.2019 Bulletin 2019/10

(21) Application number: 13700330.7

(22) Date of filing: 17.01.2013
(51) International Patent Classification (IPC): 
A61K 9/70(2006.01)
A61K 47/32(2006.01)
 A61K 31/122(2006.01)
A61K 47/38(2006.01)
(86) International application number:
PCT/EP2013/050822
(87) International publication number:
WO 2013/107810 (25.07.2013 Gazette 2013/30)

(54)

TRANSMUCOSAL ADMINISTRATION SYSTEM FOR A PHARMACEUTICAL DRUG

TRANSMUKOSALES VERABREICHUNGSSYSTEM FÜR EIN PHARMAZEUTIKUM

SYSTÈME D'ADMINISTRATION PAR VOIE TRANSMUQUEUSE POUR MÉDICAMENT

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 20.01.2012 US 201213354714

(43) Date of publication of application:
26.11.2014 Bulletin 2014/48

(60) Divisional application:
18212173.1

(73) Proprietors:
  • LTS LOHMANN Therapie-Systeme AG
    56626 Andernach (DE)
  • Santhera Pharmaceuticals (Schweiz) AG
    4133 Pratteln (CH)

(72) Inventors:
  • KRUMME, Markus
    56567 Neuwied (DE)
  • JENSEN, Keith
    Clifton, New Jersey 07013 (US)
  • DUBACH-POWELL, Judith
    CH-4104 Oberwil (CH)
  • HAUSMANN, Rudolf
    CH-4052 Basel (CH)

(74) Representative: Schweitzer, Klaus et al
Plate Schweitzer Zounek Patentanwälte Rheingaustrasse 196
65203 Wiesbaden
65203 Wiesbaden (DE)


(56) References cited: : 
EP-A1- 2 108 366
DE-A1- 19 802 050
 WO-A1-2008/019769
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).